Business
LUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM
LUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 9770V Angle PLC 12 April 2019 \n\n\n\n\nFor immediate release\n\n\n 12 April 2019\n\n\n\n \nANGLE plc (\"the Company\")\n \nLUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM \n \nLeading ANGLE customer has established a multi-centre study using Parsortix seeking to identify markers for early prediction of cancer relapse in non small cell lung cancer \n \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that a leading customer has established a multi-centre study to investigate biomarkers on circulating tumor cells (CTCs), using ANGLE's ParsortixTM system, which may give advance warning of relapse in non small cell lung cancer (NSCLC).\n \nThe study is being conducted by the Hellenic Oncology Research Group (\"Hellenic\") lead by the Principal Investigators, Associate Professor Athanasios Kotsakis and Professor Vassilis Georgoulias of the IASO General Hospital in Athens, Greece and is investigating both ctDNA (circulating tumor DNA, fragments of dead cancer cells) and CTCs. The CTC evaluation is being undertaken by the University of Athens lead by Professor Evi Lianidou. Parsortix is the only CTC system being used in the study.\n \nLung cancer has the highest incidence and mortality rate of all cancers (World Cancer Factsheet 2018: 2.1 million new cancer cases and 1.8 million deaths per annum). Even where the cancer is detected early, 45% of all NSCLC patients will suffer disease recurrence within 8 to 18 months of surgery. Where the cancer is detected late, the situation is far worse. Advance warning of potential cancer relapse in NSCLC has the potential to improve patient outcomes by allowing targeted treatment earlier than would otherwise happen. Solid tissue biopsies are impractical on the repeat basis needed for follow-up monitoring. Where they are possible, the tissue biopsy is expensive, and carries significant risk: up to 24% cause serious complications and up to 1% result in death. \n \nThe Hellenic study involves 50 operable early stage NSCLC patients having liquid biopsy blood tests prior to surgery, one month after surgery and then every three to six months until relapse. The study is scheduled to complete in December 2021. CTCs harvested from patient...